Celanese Q3 Net Sales $2.6 Billion, Up 6% Year-on-Year
Celanese reported Q3 2026 net sales of $2.6B, up 6% YoY but down 7% QoQ. EPS was $0.68 GAAP and $1.65 adjusted. Operating income was $198M, adjusted EBITDA $367M. Engineering Materials sales fell 1% YoY, while Acetyl Chain sales rose 14% YoY. Operating cash flow was $538M, free cash flow $461M.
How this was made
The 30-second read
Why it matters
Recap provides no new data; traders gain little actionable insight.
Market read
Low relevance; primarily a summary of already-public earnings.
What to watch
Potential upside from medical and electronics demand not fully priced in.
Background
Celanese's Q3 2026 earnings were released on 2026-11-02; this article repeats those figures.
Ticker impact
Q3 2026 results recapped; net sales $2.6B, EPS $0.68, higher tax rate and goodwill impairment noted.
likely slight pressure as market prices in higher tax rate and lack of new growth drivers
No fresh information beyond prior release; investors may view results as expected, limiting upside.
Market effects
Chemicals sector sees modest growth; no sector-wide catalyst.
U.S. market impact minimal.
Limited global relevance.
Counterpoint
If investors focus on segment strength in Acetyl Chain, stock could hold steadier than implied.
Key entities
- CompanyCelanese
Chemicals manufacturer, ticker CE.


